Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAdOx2 RabG Coadministered with Licensed Rabies Vaccine
NCT07168018Phase 2Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ChAdOx2 RabG in rabies (2 arms), sponsored by University of Oxford. Primary endpoints: Safety and tolerability by solicited adverse events at 7 days, Safety and tolerability by unsolicited adverse events at 28 days and 2 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ChAdOx2 RabG
03
Conditions
rabies
Beyond the preview
Go deeper on NCT07168018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168018.